Citius Oncology, Inc. (CTOR) - 10-K Summary
Business Context and Reporting Period
Company: Citius Oncology, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2025
Business Overview: Citius Oncology is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies. Its lead product is LYMPHIR (denileukin diftitox), an engineered IL-2 diphtheria toxin fusion protein approved by the FDA in August 2024 for the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL). The product was commercially launched in the U.S. in December 2025. The Company is a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Citius Pharma), which owns approximately 79% of the outstanding common stock.
Key Financial Metrics
| Metric | Year Ended Sept 30, 2025 | Year Ended Sept 30, 2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Net Loss | $(24,761,369) | $(21,148,747) |
| Operating Expenses | $23,522,750 | $20,572,747 |
| Cash and Cash Equivalents (Sept 30, 2025) | $3,924,908 | $112 |
| Working Capital | $(21,948,698) | $(21,731,551) |
| Accumulated Deficit | $(64,039,956) | $(39,278,587) |
| Stockholders' Equity | $44,866,231 | $46,140,339 |
Debt and Liquidity: The Company has a negative working capital of approximately $21.9 million. It holds a non-interest bearing promissory note payable to Citius Pharma of $3,800,111, repayable upon raising $50 million in aggregate capital. As of September 30, 2025, the Company had outstanding commitments of approximately $38.4 million to third-party suppliers and manufacturers, and $22.7 million in license fee payables.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $3.6 million (17%) compared to the prior year, driven by increases in Research and Development (R&D) expenses ($1.5M increase), General and Administrative (G&A) expenses ($0.6M increase), and Stock-based compensation ($0.8M increase).
- Inventory Build-up: Inventory increased significantly from $8.3 million to $22.3 million, reflecting the manufacturing of commercial product batches for the December 2025 launch.
- Capital Raises: During the fiscal year, the Company raised approximately $15.2 million in net proceeds from equity offerings in July and September 2025. Subsequent to the period end, an additional $18.0 million was raised in December 2025.
- License Payments: The Company paid $3.0 million to Eisai and $2.75 million to Dr. Reddy's Laboratories during the year toward milestone obligations.
Guidance, Outlook, Risks, and Contingencies
Going Concern: The independent registered public accounting firm has issued an explanatory paragraph stating there is substantial doubt about the Company's ability to continue as a going concern. Management estimates sufficient capital to fund operations through March 2026, contingent on the success of recent capital raises and future fundraising.
Outlook: The Company expects to incur losses for the foreseeable future. Commercial success depends on the market acceptance of LYMPHIR, reimbursement coverage, and the ability to raise additional capital to meet milestone payments and manufacturing commitments.
Key Risks:
- Liquidity: Failure to raise additional capital could force the Company to delay or terminate commercialization efforts.
- Milestone Payments: Significant obligations remain to Eisai ($2.9 million balance) and Dr. Reddy's ($19.75 million balance). Failure to pay could result in license termination.
- Commercialization: The Company relies on third-party sales organizations and manufacturers. Market acceptance and reimbursement rates are uncertain.
- Related Party Dependence: The Company relies heavily on Citius Pharma for funding, shared services, and management personnel.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $18.0 million raised in December 2025 combined with existing cash to cover the $38.4 million in outstanding commitments and operating burn through March 2026.
- Milestone Payment Schedule: Confirm the ability to meet the remaining $2.9 million payment to Eisai (due Dec 2025) and the $19.75 million to Dr. Reddy's to avoid license termination.
- Commercial Launch Metrics: Monitor initial sales data and reimbursement approvals for LYMPHIR following the December 2025 launch to assess revenue generation potential.
- Strategic Alternatives: Review updates on the evaluation of strategic alternatives (partnerships, mergers) mentioned as a potential path to secure funding.
- Related Party Transactions: Assess the terms of the Shared Services Agreement and the promissory note with Citius Pharma, including the trigger for repayment ($50 million capital raise threshold).